Our findings highlight several important considerations, including (i) the role of IL-1α, which is not inhibited with canakinumab alone, and (ii) the role of timing (i.e., whether IL-1 inhibition is introduced during the early stages of tumor initiation versus once tumors are fully established). The gene discussed is IL1A; the disease is neoplasm.